全文获取类型
收费全文 | 2183篇 |
免费 | 92篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 54篇 |
妇产科学 | 11篇 |
基础医学 | 283篇 |
口腔科学 | 28篇 |
临床医学 | 149篇 |
内科学 | 615篇 |
皮肤病学 | 78篇 |
神经病学 | 163篇 |
特种医学 | 61篇 |
外科学 | 442篇 |
综合类 | 7篇 |
一般理论 | 1篇 |
预防医学 | 80篇 |
眼科学 | 22篇 |
药学 | 154篇 |
中国医学 | 4篇 |
肿瘤学 | 107篇 |
出版年
2023年 | 8篇 |
2022年 | 29篇 |
2021年 | 34篇 |
2020年 | 20篇 |
2019年 | 17篇 |
2018年 | 15篇 |
2017年 | 17篇 |
2016年 | 28篇 |
2015年 | 38篇 |
2014年 | 44篇 |
2013年 | 62篇 |
2012年 | 102篇 |
2011年 | 114篇 |
2010年 | 78篇 |
2009年 | 86篇 |
2008年 | 128篇 |
2007年 | 147篇 |
2006年 | 176篇 |
2005年 | 154篇 |
2004年 | 145篇 |
2003年 | 148篇 |
2002年 | 141篇 |
2001年 | 45篇 |
2000年 | 38篇 |
1999年 | 43篇 |
1998年 | 47篇 |
1997年 | 34篇 |
1996年 | 31篇 |
1995年 | 16篇 |
1994年 | 30篇 |
1993年 | 13篇 |
1992年 | 14篇 |
1991年 | 18篇 |
1990年 | 29篇 |
1989年 | 20篇 |
1988年 | 14篇 |
1987年 | 9篇 |
1986年 | 9篇 |
1985年 | 8篇 |
1984年 | 8篇 |
1983年 | 11篇 |
1982年 | 8篇 |
1981年 | 7篇 |
1978年 | 8篇 |
1976年 | 7篇 |
1975年 | 13篇 |
1974年 | 8篇 |
1973年 | 9篇 |
1972年 | 14篇 |
1971年 | 7篇 |
排序方式: 共有2280条查询结果,搜索用时 15 毫秒
41.
S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. 总被引:3,自引:0,他引:3
Yukito Ichinose Kozo Yoshimori Hiroshi Sakai Yushi Nakai Takahiko Sugiura Masaaki Kawahara Hisanobu Niitani 《Clinical cancer research》2004,10(23):7860-7864
PURPOSE: To evaluate the efficacy and toxicity of a novel combination chemotherapeutic regimen including cisplatin with an oral anticancer agent, S-1 that consisted of tegafur, 5-chloro-2, 4-dihydroxypyridine, and potassium oxonate, for non-small-cell lung cancer (NSCLC) patients. EXPERIMENTAL DESIGN: In this phase II trial, patients with locally advanced and metastatic NSCLC were treated with the oral administration of S-1 at 40 mg/m(2) twice a day for 21 consecutive days while cisplatin (60 mg/m(2)) was administered intravenously on day 8. This schedule was repeated every 5 weeks. RESULTS: Of 56 patients enrolled in the study, 55 patients were eligible and analyzed. The median number of cycles administered was 3 (range, 1-12 cycles). Among these 55 patients, one complete response and 25 partial responses were observed with an overall response rate of 47% (95% confidence interval, 34-61%). The median survival time was 11 months and the 1-year survival rate was 45%. Hematologic toxicities of grades 3 and 4 included neutropenia (29%) and anemia (22%). No grade 4 nonhematologic toxicity was observed. Grade 3 toxicity included anorexia (13%), vomiting (7%), or diarrhea (7%). CONCLUSIONS: S-1 plus cisplatin combination chemotherapy showed a promising effectiveness with acceptable toxicity rates in patients with advanced NSCLC. These results warrant further investigations of this regimen including a randomized controlled trial for its use as a first line treatment for NSCLC. 相似文献
42.
Yaw-Bin Huang Yi-Hung Tsai Wan-Chiech Yang Jui-Sheng Chang Pao-Chu Wu Kozo Takayama 《European journal of pharmaceutics and biopharmaceutics》2004,58(3):607-614
The purpose of this study was to develop and optimize the propranolol once-daily extended release formulations containing HPMC, Microcrystalline cellulose (MCC) and lactose. In vitro studies, the response surface methodology and multiple response optimization utilizing the polynomial equation were used to search for the optimal formulation with specific release rate at different time intervals. The constrained mixture experimental design was used to prepare systematic model formulations, which were composed of three formulation variables: the content of HPMC (X(1)) MCC (X(2)) and lactose (X(3)). The drug release percent at 1.5, 4, 8, 14 and 24 h were the target responses and were restricted to 15-30, 35-55, 55-75, 75-90 and 90-110%, respectively. The results showed that the optimized formulation provided a dissolution pattern equivalent to the predicted curve, which indicated that the optimal formulation could be obtained using response surface methodology. The mechanism of drug release from HMPC matrix tablets followed non-Fickian diffusion. In the vivo study, the MRT was prolonged for matrix tablets when compared with commercial immediate release tablets. Furthermore, a linear relationship between in vitro dissolution and in vivo absorption was observed in the beagle dogs. 相似文献
43.
44.
45.
Yumani Kuba Sonoko Ishino Takeshi Yamagami Masahiro Tokuhara Tamotsu Kanai Ryosuke Fujikane Hiromi Daiyasu Haruyuki Atomi Yoshizumi Ishino 《Genes to cells : devoted to molecular & cellular mechanisms》2012,17(11):923-937
The DNA sliding clamp is a multifunctional protein involved in cellular DNA transactions. In Archaea and Eukaryota, proliferating cell nuclear antigen (PCNA) is the sliding clamp. The ring‐shaped PCNA encircles double‐stranded DNA within its central hole and tethers other proteins on DNA. The majority of Crenarchaeota, a subdomain of Archaea, have multiple PCNA homologues, and they are capable of forming heterotrimeric rings for their functions. In contrast, most organisms in Euryarchaeota, the other major subdomain, have a single PCNA forming a homotrimeric ring structure. Among the Euryarchaeota whose genome is sequenced, Thermococcus kodakarensis is the only species with two genes encoding PCNA homologues on its genome. We cloned the two genes from the T. kodakarensis genome, and the gene products, PCNA1 and PCNA2, were characterized. PCNA1 stimulated the DNA synthesis reactions of the two DNA polymerases, PolB and PolD, from T. kodakarensis in vitro. PCNA2, however, only had an effect on PolB. We were able to disrupt the gene for PCNA2, whereas gene disruption for PCNA1 was not possible, suggesting that PCNA1 is essential for DNA replication. The sensitivities of the Δpcna2 mutant strain to ultraviolet irradiation (UV), methyl methanesulfonate (MMS) and mitomycin C (MMC) were indistinguishable from those of the wild‐type strain. 相似文献
46.
47.
Propensity score‐matched study of laparoscopic and open surgery for colorectal cancer in rural hospitals 下载免费PDF全文
Toshihiro Nakao Mitsuo Shimada Kozo Yoshikawa Jun Higashijima Takuya Tokunaga Masaaki Nishi Chie Takasu Hideya Kashihara Ichio Suzuka Takashi Nishizaki Hiroshi Okitsu Toshiyuki Yagi Hidenori Miyake Murato Miura Mitsutoshi Fukuyama Daisuke Wada Yoshiaki Bando 《Journal of gastroenterology and hepatology》2016,31(10):1700-1704
48.
Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice 下载免费PDF全文
Elena Elstner Carsten Müller Kozo Koshizuka Elizabeth A. Williamson Dorothy Park Hiroya Asou Peter Shintaku Jonathan W. Said David Heber H. Phillip Koeffler 《Proceedings of the National Academy of Sciences of the United States of America》1998,95(15):8806-8811
Induction of differentiation and apoptosis in cancer cells through ligands of nuclear hormone receptors (NHRs) is a novel and promising approach to cancer therapy. All-trans-retinoic acid (ATRA), an RA receptor-specific NHR ligand, is now used for selective cancers. The NHR, peroxisome proliferator-activated receptor γ (PPARγ) is expressed in breast cancer cells. Activation of PPARγ through a synthetic ligand, troglitazone (TGZ), and other PPARγ-activators cause inhibition of proliferation and lipid accumulation in cultured breast cancer cells. TGZ (10−5 M, 4 days) reversibly inhibits clonal growth of MCF7 breast cancer cells and the combination of TGZ (10−5 M) and ATRA (10−6 M, 4 days) synergistically and irreversibly inhibits growth and induces apoptosis of MCF7 cells, associated with a dramatic decrease of their bcl-2 protein levels. Similar effects are noted with in vitro cultured breast cancer tissues from patients, but not with normal breast epithelial cells. The observed apoptosis mediated by TGZ and ATRA may be related to the striking down-regulation of bcl-2, because forced over-expression of bcl-2 in MCF7 cells cultured with TGZ and ATRA blocks their cell death. TGZ significantly inhibits MCF7 tumor growth in triple immunodeficient mice. Combined administration of TGZ and ATRA causes prominent apoptosis and fibrosis of these tumors without toxic effects on the mice. Taken together, this combination may provide a novel, nontoxic and selective therapy for human breast cancers. 相似文献
49.
Masayo Kagami Kenji Kurosawa Osamu Miyazaki Fumitoshi Ishino Kentaro Matsuoka Tsutomu Ogata 《European journal of human genetics : EJHG》2015,23(11):1488-1498
Paternal uniparental disomy 14 (UPD(14)pat) and epimutations and microdeletions affecting the maternally derived 14q32.2 imprinted region lead to a unique constellation of clinical features such as facial abnormalities, small bell-shaped thorax with a coat-hanger appearance of the ribs, abdominal wall defects, placentomegaly, and polyhydramnios. In this study, we performed comprehensive clinical studies in patients with UPD(14)pat (n=23), epimutations (n=5), and microdeletions (n=6), and revealed several notable findings. First, a unique facial appearance with full cheeks and a protruding philtrum and distinctive chest roentgenograms with increased coat-hanger angles to the ribs constituted the pathognomonic features from infancy through childhood. Second, birth size was well preserved, with a median birth length of ±0 SD (range, −1.7 to +3.0 SD) and a median birth weight of +2.3 SD (range, +0.1 to +8.8 SD). Third, developmental delay and/or intellectual disability was invariably present, with a median developmental/intellectual quotient of 55 (range, 29–70). Fourth, hepatoblastoma was identified in three infantile patients (8.8%), and histological examination in two patients showed a poorly differentiated embryonal hepatoblastoma with focal macrotrabecular lesions and well-differentiated hepatoblastoma, respectively. These findings suggest the necessity of an adequate support for developmental delay and periodical screening for hepatoblastoma in the affected patients, and some phenotypic overlap between UPD(14)pat and related conditions and Beckwith–Wiedemann syndrome. On the basis of our previous and present studies that have made a significant contribution to the clarification of underlying (epi)genetic factors and the definition of clinical findings, we propose the name ‘Kagami–Ogata syndrome'' for UPD(14)pat and related conditions. 相似文献
50.